Significance of the Vascular Concentration of Angiotensin II-Receptor Blockers on the Mechanism of Lowering Blood Pressure in Spontaneously Hypertensive Rats

被引:7
作者
Takai, Shinji [1 ]
Jin, Denan [1 ]
Sakonjo, Hiroshi [3 ]
Takubo, Takayuki [2 ]
Nakanishi, Toyofumi [2 ]
机构
[1] Osaka Med Coll, Dept Pharmacol, Takatsuki, Osaka 5698686, Japan
[2] Osaka Med Coll, Dept Clin & Lab Med, Takatsuki, Osaka 5698686, Japan
[3] Nissei BILIS, Shiga Res Ctr, Shiga 5280052, Japan
关键词
angiotensin II; angiotensin II receptor blocker; hypertension; imaging mass spectrometry; vascular contraction; IMAGING MASS-SPECTROMETRY; CONVERTING ENZYME; MANAGEMENT; MORBIDITY; MORTALITY; INTERVENTION; GUIDELINES; SOCIETY;
D O I
10.1254/jphs.13167FP
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To clarify the hypotensive mechanism of angiotensin II receptor blockers (ARBs), drug concentrations in plasma and vascular tissues were measured using matrix-assisted laser desorption ionization time-of-flight mass spectrometry and imaging mass spectrometry. In spontaneously hypertensive rats, systolic blood pressure (SBP) was measured 2 and 24 h after administration of candesartan cilexetil (0.3, 1, or 3 mg/kg) or azilsartan (0.3, 1, or 3 mg/kg). SBP was similarly lowered 2 h after administration of azilsartan or candesartan cilexetil, but it was significantly lower in the azilsartan-treated group than in the candesartan cilexetil-treated group at 24 h. Angiotensin II induced vascular contractions were similarly attenuated 2 h after administration of these drugs, and the contractions were significantly lower in the azilsartan-treated group at 24 h. Although plasma concentration was significantly lower in the azilsartan-treated group at 24 h, vascular concentration of azilsartan was significantly greater than that of candesartan. Significant correlations between SBP and vascular concentrations were observed both at 2 and 24 h, while no significant correlation was observed between plasma and vascular concentrations. In conclusion, the mechanism of ARB-induced hypotension is likely to depend on vascular concentrations rather than plasma concentrations.
引用
收藏
页码:371 / 379
页数:9
相关论文
共 21 条
  • [1] Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
    Brown, MJ
    Palmer, CR
    Castaigne, A
    de Leeuw, PW
    Mancia, G
    Rosenthal, T
    Ruilope, LM
    [J]. LANCET, 2000, 356 (9227) : 366 - 372
  • [2] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    Chobanian, AV
    Bakris, GL
    Black, HR
    Cushman, WC
    Green, LA
    Izzo, JL
    Jones, DW
    Materson, BJ
    Oparil, S
    Wright, JT
    Roccella, EJ
    [J]. HYPERTENSION, 2003, 42 (06) : 1206 - 1252
  • [3] MALDI-FTICR imaging mass spectrometry of drugs and metabolites in tissue
    Cornett, Dale S.
    Frappier, Sara L.
    Caprioli, Richard M.
    [J]. ANALYTICAL CHEMISTRY, 2008, 80 (14) : 5648 - 5653
  • [4] SPECTROPHOTOMETRIC ASSAY AND PROPERTIES OF ANGIOTENSIN-CONVERTING ENZYME OF RABBIT LUNG
    CUSHMAN, DW
    CHEUNG, HS
    [J]. BIOCHEMICAL PHARMACOLOGY, 1971, 20 (07) : 1637 - +
  • [5] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
    Dahlöf, B
    Devereux, RB
    Kjeldsen, SE
    Julius, S
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristiansson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    [J]. LANCET, 2002, 359 (9311) : 995 - 1003
  • [6] Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981
  • [7] Pharmacological profiles of a novel non-peptide angiotensin II type I receptor antagonist HR720 in vitro and in vivo
    Jin, D
    Song, K
    Oka, Y
    Takai, S
    Shiota, N
    Miyazaki, M
    [J]. JAPANESE JOURNAL OF PHARMACOLOGY, 1997, 75 (03) : 259 - 266
  • [8] Proposal of a new strategy for ambulatory blood pressure profile-based management of resistant hypertension in the era of renal denervation
    Kario, Kazuomi
    [J]. HYPERTENSION RESEARCH, 2013, 36 (06) : 478 - 484
  • [9] Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres
    Kohara, Y
    Kubo, K
    Imamiya, E
    Wada, T
    Inada, Y
    Naka, T
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (26) : 5228 - 5235
  • [10] 2013 ESH/ESC Guidelines for themanagement of arterial hypertension The Task Force for the management ofarterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC)
    Mancia, Giuseppe
    Fagard, Robert
    Narkiewicz, Krzysztof
    Redon, Josep
    Zanchetti, Alberto
    Boehm, Michael
    Christiaens, Thierry
    Cifkova, Renata
    De Backer, Guy
    Dominiczak, Anna
    Galderisi, Maurizio
    Grobbee, Diederick E.
    Jaarsma, Tiny
    Kirchhof, Paulus
    Kjeldsen, Sverre E.
    Laurent, Stephane
    Manolis, Athanasios J.
    Nilsson, Peter M.
    Ruilope, Luis Miguel
    Schmieder, Roland E.
    Sirnes, Per Anton
    Sleight, Peter
    Viigimaa, Margus
    Waeber, Bernard
    Zannad, Faiez
    Redon, Josep
    Dominiczak, Anna
    Narkiewicz, Krzysztof
    Nilsson, Peter M.
    Burnier, Michel
    Viigimaa, Margus
    Ambrosioni, Ettore
    Caufield, Mark
    Coca, Antonio
    Olsen, Michael Hecht
    Schmieder, Roland E.
    Tsioufis, Costas
    van de Borne, Philippe
    Zamorano, Jose Luis
    Achenbach, Stephan
    Baumgartner, Helmut
    Bax, Jeroen J.
    Bueno, Hector
    Dean, Veronica
    Deaton, Christi
    Erol, Cetin
    Fagard, Robert
    Ferrari, Roberto
    Fagard, David Hasdai
    Hoes, Arno W.
    [J]. JOURNAL OF HYPERTENSION, 2013, 31 (07) : 1281 - 1357